Ocular Therapeutix, Inc.
corporate_fare Company Profile
Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for OCUL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for OCUL spans 10-Q, 8-K, DEFA14A, DEF 14A.
Recent high-impact activity:
- Ocular Therapeutix 10-Q: $94.8M Q3 Loss, $530.6M Cash, EyePoint Suit Settled
- Ocular Therapeutix Posts $94.8M Q3 Loss; AXPAXLI NDA Still Set for Q4 2026
- Ocular Therapeutix Posts $94.8M Third-Quarter Loss
- FDA Pre-NDA Meeting Confirms AXPAXLI Path for Wet AMD, NDA on Track for Q4
- Ocular Therapeutix Reports Q2 Results, Confirms Q4 AXPAXLI NDA Submission, Extends Cash Runway into 2028
Financial Snapshot
Short Interest & Short Volume
10.14 days to coverFINRA reported short interest of 28,998,345 shares in OCUL as of the October 30, 2026 settlement, a 0.8% increase from the prior period — about 10.1 days to cover at its recent average daily volume. On November 20, 2026, 34.9% of OCUL volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.